Table 5

Multivariate regression results for incidence of intensive care unit admission

	Estimate	SE	Statistic	P value	OR	OR SE
Patient characteristics
Age	−0.03	0.00	−5.41	<0.001	0.97	0.00
Male gender	0.11	0.12	0.89	0.37	1.12	0.28
Charlson Comorbidity Index (excluding cancer)	0.06	0.03	2.36	0.02	1.06	0.07
Immune checkpoint inhibitor use
CTLA4 therapy	0.36	0.25	1.47	0.14	1.44	0.29
Combination ICI therapy	0.21	0.22	0.96	0.34	1.23	0.46
Underlying conditions
Other cancer	0.11	0.17	0.67	0.5	1.12	0.24
Melanoma	−0.07	0.19	−0.38	0.7	0.93	0.19
Renal cell carcinoma	0.11	0.2	0.55	0.58	1.12	0.03
Regional information
Zip code average income (normalized)	0.17	0.06	2.72	0.01	1.19	0.08
Zip code average unemployment (normalized)	0.05	0.07	0.68	0.5	1.05	0.37
East South Central
Mid-Atlantic	−0.08	0.2	−0.39	0.7	0.92	0.16
Mountain	0.21	0.29	0.7	0.48	1.23	0.25
New England	−0.58	0.37	−1.56	0.12	0.56	0.21
Pacific	0.15	0.25	0.6	0.55	1.16	0.14
South Atlantic	−0.1	0.21	−0.48	0.63	0.91	0.17
West North Central	0.11	0.35	0.31	0.76	1.11	0.27
West South Central	0.22	0.22	1	0.32	1.24	0.37

Note: reference group is female patients on programmed cell death protein 1or programmed death-ligand 1 therapy with Lung Cancer in East North Central Region.
Other cancers include: bladder cancer, colon cancer, head and neck squamous cell carcinoma Hodgkin’s lymphoma, gastric cancer, liver cancer, cervical cancer, and Merkel cell carcinoma.
CTLA4, cytotoxic T lymphocyte-associated 4; ICI, immune checkpoint inhibitor.